From: The importance of N6-methyladenosine modification in tumor immunity and immunotherapy
Cancer/Disease | Drug | Target | Role | Mechanism |
---|---|---|---|---|
AML | STM2457 | METTL3 | Inhibitor | Weaken the proliferation of AML stem cells or leukemia |
SPI1 | METTL14 | Regulator | Promote terminal myeloid differentiation of normal HSPCs/AML Inhibit AML cell survival | |
CS1/CS2 | FTO | Inhibitor | Increase the sensitivity of AML cells to T cell toxicity | |
R-2HG | FTO | Inhibitor | Inhibit the proliferation of AML and weaken aerobic glycolysis in sensitive leukemic cells | |
FB23-2 | FTO | Inhibitor | Suppress proliferation and promote the differentiation of AML | |
Rhein | FTO | Inhibitor | Overcome tyrosine kinase inhibitor resistance | |
GBM | MA/MA2 | FTO | Inhibitor | Suppress the growth and self-renewal of GSCs |
Melanoma | ALK-04 | ALKBH5 | Inhibitor | Regulate the express of Mct4/Scl16a3 and lactic acid |
BC | MO-I-500 | FTO | Inhibitor | Suppress survival of BC cells by decreasing IRX3 proteins |
LUAD | PKE Sorafenib | YTHDC2 | Regulator | Suppress SLC7A11-dependent antioxidant function |
Testicular damage | MEHP | FTO | Inhibitor | Regulate reduction of testosterone and increase of apoptosis |